RxDoctor Payments Data

Lauren Policky, PA

Physician Assistant · Lincoln, NENPI 1427582576

Payments from drug & device makers

$1,712in general payments, 2019–2025

Across 33 payments — averaging $51.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1K
  • Novartis$110
  • Sanofi-aventis U.S. LLC$75
  • AbbVie$57
  • Daiichi Sankyo Inc.$46
  • Gilead$39
  • plus $254 from 12 others
$1,255in research payments, 2019–2025

Across 8 payments — averaging $156.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$1K

What the payments were for

  • Travel & lodging$86250%
  • Food & beverage$77545%
  • Education$754%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,712 in reported general payments places this provider in the 80th percentile of 1,127 physician assistant providers in Nebraska.

See all physician assistant providers in Nebraska

Medicare billing

Part B allowed, 2024
$9,582
Medicare patients
74
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib23$366,827
IbrancePalbociclib23$338,699
CalquenceAcalabrutinib Maleate13$189,951
VenclextaVenetoclax12$146,422
XareltoRivaroxaban77$46,621
EliquisApixaban35$27,849
Abiraterone Acetate11$3,217
Letrozole82$3,063
Anastrozole144$1,938
Fluconazole14$1,783
Hydroxyurea74$1,670
Acyclovir94$1,267
Imatinib Mesylate13$1,089
Tamoxifen Citrate16$456
Potassium Chloride22$382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$21$366,54858 claims
AstraZenecaCalquence$17$189,95113 claims
AbbVieVenclexta$57$146,42212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,127 physician assistant providers in Nebraska.

Other physician assistant in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →